Skip to main content
. 2018 Aug 24;11:1756284818787400. doi: 10.1177/1756284818787400

Figure 1.

Figure 1.

Novel classes of therapies for cholestatic liver diseases.

FGF 19, fibroblast growth factor 19; FXR, farnesoid X receptor; HCO3, bicarbonate; norUDCA, 24-norursodeoxycholic acid; PPAR, peroxisome proliferator-activated receptor.